Duration of treatment in postmenopausal osteoporosis: how long to treat and what are the consequences of cessation of treatment?

Rheum Dis Clin North Am. 2011 Aug;37(3):323-36, v. doi: 10.1016/j.rdc.2011.07.007.

Abstract

Although a variety of medications are effective for the treatment of postmenopausal osteoporosis, there is concern that long-term use may incur side effects. Consequently, some have proposed discontinuing or temporarily suspending treatment after a defined period of time. As the benefits of fracture risk reduction may recede during this "drug holiday", the clinician may be faced with deciding when to resume therapy (and with which agent) while avoiding the possible cumulative risk of side effects. This article summarizes data regarding length of treatment and the effects of cessation of treatment on bone density, bone turnover markers, and fracture risk.

MeSH terms

  • Bone Density Conservation Agents / administration & dosage*
  • Bone Density Conservation Agents / adverse effects*
  • Bone and Bones / drug effects*
  • Bone and Bones / physiology
  • Estrogen Replacement Therapy / adverse effects
  • Estrogen Replacement Therapy / methods
  • Female
  • Fractures, Bone / epidemiology
  • Fractures, Bone / prevention & control
  • Humans
  • Middle Aged
  • Osteoporosis, Postmenopausal / drug therapy*
  • Osteoporosis, Postmenopausal / epidemiology
  • Osteoporosis, Postmenopausal / physiopathology
  • Practice Guidelines as Topic
  • Risk Factors
  • Substance Withdrawal Syndrome / diagnosis*
  • Substance Withdrawal Syndrome / epidemiology

Substances

  • Bone Density Conservation Agents